Darktrace plc specializes in advanced cyber security solutions, serving a global client base across the United Kingdom, the United States, Canada, and Europe. The firm develops sophisticated technologies designed to autonomously detect and neutralize evolving cyber threats. Its product portfolio features the Enterprise Immune System, engineered to uncover previously unseen digital dangers, and the Industrial Immune System, which fortifies the integrity and resilience of operational technologies against novel vulnerabilities. Furthermore, their Cyber AI Analyst leverages artificial intelligence to automatically investigate, prioritize, and report on the scope of security incidents. Complementing these, Darktrace Antigena provides autonomous response capabilities, offering proactive defense across enterprise digital infrastructures by integrating with existing security products. Darktrace caters to a broad spectrum of clients, including organizations within critical national infrastructure, financial services, technology, healthcare, media, and academic sectors. The company was established in 2013 and is headquartered in Cambridge, United Kingdom.